Effects of a SARS-associated coronavirus vaccine in monkeys

Wentao Gao, Azaibi Tamin, Adam Soloff, Leonardo D'Aiuto, Edward Nwanegbo, Paul D. Robbins, William J. Bellini, Simon Barratt-Boyes, Andrea Gambotto

Research output: Contribution to journalArticlepeer-review

199 Scopus citations

Abstract

The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of coronavirus. Here, we have investigated the ability of adenoviral delivery of codon-optimised SARS-CoV strain Urbani structural antigens spike protein S1 fragment, membrane protein, and nucleocapsid protein to induce virus-specific broad immunity in rhesus macaques. We immunised rhesus macaques intramuscularly with a combination of the three Ad5-SARS-CoV vectors or a control vector and gave a booster vaccination on day 28. The vaccinated animals all had antibody responses against spike protein S1 fragment and T-cell responses against the nucleocapsid protein. All vaccinated animals showed strong neutralising antibody responses to SARS-CoV infection in vitro. These results show that an adenoviral-based vaccine can induce strong SARS-CoV-specific immune responses in the monkey, and hold promise for development of a protective vaccine against the SARS causal agent.

Original languageEnglish (US)
Pages (from-to)1895-1896
Number of pages2
JournalLancet
Volume362
Issue number9399
DOIs
StatePublished - Dec 6 2003
Externally publishedYes

Bibliographical note

Funding Information:
This work was supported by National Heart Lung and Blood Institute, Program of Excellence in Gene Therapy supplement Grants U01 HL66949–01S1 to A Gambotto. The authors thank K Okada and H Sun for assistance with adenoviral preparation. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or in the writing of the report.

Fingerprint Dive into the research topics of 'Effects of a SARS-associated coronavirus vaccine in monkeys'. Together they form a unique fingerprint.

Cite this